CN1516705A - 新的芳基果糖-1,6-二磷酸酶抑制剂 - Google Patents

新的芳基果糖-1,6-二磷酸酶抑制剂 Download PDF

Info

Publication number
CN1516705A
CN1516705A CNA018090214A CN01809021A CN1516705A CN 1516705 A CN1516705 A CN 1516705A CN A018090214 A CNA018090214 A CN A018090214A CN 01809021 A CN01809021 A CN 01809021A CN 1516705 A CN1516705 A CN 1516705A
Authority
CN
China
Prior art keywords
aryl
substituted
chr
atoms
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018090214A
Other languages
English (en)
Chinese (zh)
Inventor
Bc
B·C·波克赛尔
党群
K·R·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of CN1516705A publication Critical patent/CN1516705A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA018090214A 2000-03-08 2001-03-07 新的芳基果糖-1,6-二磷酸酶抑制剂 Pending CN1516705A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18775000P 2000-03-08 2000-03-08
US60/187,750 2000-03-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2005100720821A Division CN1699383A (zh) 2000-03-08 2001-03-07 新的芳基果糖－1,6－二磷酸酶抑制剂

Publications (1)

Publication Number Publication Date
CN1516705A true CN1516705A (zh) 2004-07-28

Family

ID=22690309

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA018090214A Pending CN1516705A (zh) 2000-03-08 2001-03-07 新的芳基果糖-1,6-二磷酸酶抑制剂
CNA2005100720821A Pending CN1699383A (zh) 2000-03-08 2001-03-07 新的芳基果糖－1,6－二磷酸酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005100720821A Pending CN1699383A (zh) 2000-03-08 2001-03-07 新的芳基果糖－1,6－二磷酸酶抑制剂

Country Status (20)

Country Link
US (2) US6919322B2 (https=)
EP (2) EP1265907B9 (https=)
JP (1) JP2003525944A (https=)
KR (1) KR20020079988A (https=)
CN (2) CN1516705A (https=)
AT (1) ATE350385T1 (https=)
AU (2) AU2001245532B2 (https=)
BR (1) BR0109062A (https=)
CA (1) CA2401706A1 (https=)
CZ (1) CZ20023018A3 (https=)
DE (1) DE60125734T2 (https=)
HU (1) HUP0300344A3 (https=)
IL (2) IL151248A0 (https=)
MX (1) MXPA02008722A (https=)
NO (1) NO20024240L (https=)
PL (1) PL357251A1 (https=)
RU (1) RU2002126616A (https=)
SK (1) SK12722002A3 (https=)
WO (1) WO2001066553A2 (https=)
ZA (1) ZA200207004B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279283A (zh) * 2007-08-13 2017-01-04 症变治疗公司 新颖的葡糖激酶活化剂

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
KR100818845B1 (ko) 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
JP2003525944A (ja) 2000-03-08 2003-09-02 メタバシス・セラピューティクス・インコーポレイテッド 新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU2003252676A1 (en) * 2002-07-23 2004-02-09 Sankyo Company, Limited Preventive for the onset of diabetes
FR2846327B1 (fr) * 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
EP1825854A1 (en) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
EP2058308A1 (fr) 2007-11-12 2009-05-13 Merck Sante Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
US9006568B2 (en) * 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
AU2013251109B2 (en) * 2012-04-20 2017-08-24 Bayer Cropscience Ag N-cycloalkyl-N-[(heterocyclylphenyl)methylene]-(thio)carboxamide derivatives
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9691986B2 (en) 2012-12-03 2017-06-27 Solarmer Energy, Inc. Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
WO2017058406A1 (en) 2015-10-01 2017-04-06 Phillips 66 Company Formation of films for organic photovoltaics
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
JP7072557B2 (ja) 2016-07-22 2022-05-20 ブリストル－マイヤーズ スクイブ カンパニー グルコキナーゼ活性化剤およびその使用方法
CN111116647B (zh) * 2019-12-02 2021-08-24 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL72851C (https=) * 1950-10-31 1900-01-01
US2683168A (en) * 1950-12-22 1954-07-06 California Research Corp Preparation of organo phosphonyl chlorides
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
GB2043073B (en) * 1979-02-13 1983-05-11 Symphar Sa Mono-and diphosphonate compounds
US4640701A (en) * 1984-04-17 1987-02-03 Ciba-Geigy Corporation Herbicidal phosphonic acid and phosphinic acid derivatives
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5045557A (en) * 1987-03-20 1991-09-03 Schering Agrochemicals Ltd. Imidazable fungicides and use thereof
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US4968790A (en) 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
DE69014562T2 (de) 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5208235A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole derivatives
US5278153A (en) * 1992-05-18 1994-01-11 E. R. Squibb & Sons, Inc. Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
CA2322487C (en) 1998-03-06 2010-07-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO1999047549A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
KR100818845B1 (ko) 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
DE19843383A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
PL352756A1 (en) * 1998-12-24 2003-09-08 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
MXPA01008937A (es) 1999-03-05 2004-04-05 Metabasis Therapeutics Inc Nuevos profarmacos que contienen fosforo.
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
JP2003525944A (ja) * 2000-03-08 2003-09-02 メタバシス・セラピューティクス・インコーポレイテッド 新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1372660A2 (en) 2000-07-06 2004-01-02 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
JP2008510018A (ja) 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279283A (zh) * 2007-08-13 2017-01-04 症变治疗公司 新颖的葡糖激酶活化剂
US10174062B2 (en) 2007-08-13 2019-01-08 Metabasis Therapeutics, Inc. Activators of glucokinase

Also Published As

Publication number Publication date
CA2401706A1 (en) 2001-09-13
BR0109062A (pt) 2002-11-26
US20020040014A1 (en) 2002-04-04
AU4553201A (en) 2001-09-17
IL151248A0 (en) 2003-04-10
PL357251A1 (en) 2004-07-26
WO2001066553A3 (en) 2002-03-14
SK12722002A3 (sk) 2003-04-01
EP1607401A1 (en) 2005-12-21
US6919322B2 (en) 2005-07-19
MXPA02008722A (es) 2004-05-05
NO20024240L (no) 2002-11-08
RU2002126616A (ru) 2004-03-20
JP2003525944A (ja) 2003-09-02
HUP0300344A3 (en) 2007-05-29
US20050176684A1 (en) 2005-08-11
KR20020079988A (ko) 2002-10-21
HUP0300344A2 (hu) 2003-06-28
HK1051865A1 (en) 2003-08-22
CZ20023018A3 (cs) 2003-01-15
US7371739B2 (en) 2008-05-13
EP1265907B1 (en) 2007-01-03
CN1699383A (zh) 2005-11-23
IL151248A (en) 2007-06-17
EP1265907B9 (en) 2007-05-09
ZA200207004B (en) 2003-12-01
WO2001066553A2 (en) 2001-09-13
AU2001245532B2 (en) 2005-08-11
EP1265907A2 (en) 2002-12-18
ATE350385T1 (de) 2007-01-15
DE60125734D1 (en) 2007-02-15
DE60125734T2 (de) 2007-10-25
NO20024240D0 (no) 2002-09-05

Similar Documents

Publication Publication Date Title
CN1516705A (zh) 新的芳基果糖-1,6-二磷酸酶抑制剂
CN1215076C (zh) 新的果糖1,6－二磷酸酶的杂芳族抑制剂
CN1434828A (zh) 新的双氨基化膦酸酯前药
CN1280267C (zh) 磺酰氨基羧酸
CN1353719A (zh) 新的含磷前药
AU2001245532A1 (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
CN1934120A (zh) 新的胃促胰酶抑制剂
CN1350466A (zh) 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
CN1599612A (zh) Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
CN1224388C (zh) Ap/amp的改良前药形式
CN1187360C (zh) 有羧基肽酶b抑制活性的膦酸衍生物
CN1489596A (zh) α-取代的β-氨基乙基膦酸酯类化合物
CN1832950A (zh) 丝氨酸蛋白酶抑制剂的含哌嗪膦酸化合物
CN100349904C (zh) 新的果糖1,6－二磷酸酶的杂芳族抑制剂
CN1443190A (zh) 基质金属蛋白酶抑制剂
CN1027694C (zh) N-甲基-d-天冬氨酸拮抗剂的制备方法
HK1085743B (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
HK1085743A1 (zh) 新的果糖1，6-二磷酸酶的雜芳族抑制劑
CN1309660A (zh) 用作药物的次膦酸和膦酸衍生物
HK1099653A (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CN1196057A (zh) 取代的次膦酸化合物及其作为药物的用途
HK1083629A (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
HK1051865B (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
CN1733779A (zh) 新的含磷前药
CN1222078A (zh) 用作naalad酶抑制剂的氧膦基衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication